Structure Therapeutics (NASDAQ:GPCR) Posts Earnings Results, Misses Estimates By $0.33 EPS

Structure Therapeutics (NASDAQ:GPCR) posted its quarterly earnings results on Monday. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.33), FiscalAI reports.

Structure Therapeutics Stock Up 5.2%

Shares of Structure Therapeutics stock traded up $1.06 during trading on Monday, reaching $21.41. The company’s stock had a trading volume of 1,235,627 shares, compared to its average volume of 966,527. Structure Therapeutics has a 1-year low of $18.70 and a 1-year high of $94.90. The company has a 50-day simple moving average of $30.52 and a two-hundred day simple moving average of $47.81. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -21.41 and a beta of -1.12.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Citigroup reiterated a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Citizens Jmp reissued a “market outperform” rating and issued a $110.00 price objective on shares of Structure Therapeutics in a research report on Wednesday, September 9th. HC Wainwright restated a “buy” rating on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Weiss Ratings raised shares of Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. Finally, Wall Street Zen lowered shares of Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $110.91.

Structure Therapeutics Company Profile

Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates.

The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.

Founded in 2016, the company has operations in the United States and China.